Pfizer says its COVID-19 pill cuts disease’s worst risks by 89% : Coronavirus Updates : NPR

Pfizer’s logo hangs at the company’s headquarters in New York. Pfizer says its experimental pill for COVID-19 reduces hospitalization and mortality in patients with mild to moderate infections by about 90 percent.

Mark Lenihan / AP


Hide captions

Toggle caption.

Mark Lenihan / AP


Pfizer’s logo hangs at the company’s headquarters in New York. Pfizer says its experimental pill for COVID-19 reduces hospitalization and mortality in patients with mild to moderate infections by about 90 percent.

Mark Lenihan / AP

Pfizer says its COVID-19 pill reduced the risk of hospitalization or death by 89%, in a clinical trial that tested the drug in adults with the disease, which is associated with higher health. There were also risk groups.

The oral medication is called Paxlovid. Like Merck’s new pill. Approved in the UK on Thursday, Pfizer said the drug showed good results within the first five days of use of the first symptoms of COVID-19.

Based on the strength of the trial results, Pfizer says it will stop involving people in further clinical trials of the pill and instead send the results so far to the US Food and Drug Administration, so that emergency Permission to use as.

“These data show that our oral antiviral candidates, if approved or permitted by regulatory authorities, can save patients’ lives, reduce the severity of COVID-19 infections, and Has the potential to eliminate admissions to nine hospitals, ”said Albert Borla, Pfizer CEO and Chairman.

Both Pfizer and Merck’s antiviral drugs attack the corona virus by interfering with its ability to replicate itself.

Pfizer says the pill also helps in combination with a low dose of Ratonavir, a drug used to treat HIV / AIDS. Ritonavir helps protease inhibitors, such as Pfizer, which lasts longer in the human body, making it more effective in fighting the virus.

Officials in both the United States and the United Kingdom say effective COVID-19 tablets could be game-changers in the fight against the epidemic, as the tablets can be easily delivered at home. RegeneronAntibody Cocktail has become a key tool in the rush of medical workers to prevent the worst outcomes for those who have contracted COVID-19, but for the treatment of monoclonal antibodies either intravenous infusion Or need a series of shots.

Pfizer says the drug could be prescribed to reduce the severity of the disease in cod patients as well as to reduce the chances of adults being infected with the corona virus.

“It has demonstrated a powerful antiviral in vitro activity against a variety of circulating anxiety, as well as other well-known corona viruses, suggesting its potential as a treatment for several types of corona virus infections. The company announced the results of the drug trial.

Leave a Comment

Your email address will not be published. Required fields are marked *